Physician
Daniel L. Burkhead, MD LTD
Daniel L. Burkhead, MD LTD was paid $94K by Medicaid between Jun 2018 and Nov 2024, across 21 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 97% of everything it billed.
33Billing provider infoDANIEL L. BURKHEAD, MD LTD
LAS VEGAS, NV 89129
LAS VEGAS, NV 89129
33aNPI1942253075assigned 05/18/2006
33bProvider typeInterventional Pain Medicine Physician
28Total paid$94K
24GClaims21,901
24DCodes billed21
24AFirst – last monthJun 2018 – Nov 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Nevada
Rank by total paid#8 of 13
Median peer was paid$117K
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,369 | $3K | |
| 2019 | 8,725 | $19K | |
| 2020 | 4,423 | $15K | |
| 2021 | 2,948 | $21K | |
| 2022 | 1,320 | $13K | |
| 2023 | 1,972 | $12K | |
| 2024incomplete | 1,144 | $11K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 97% | 3,809 | 3,429 | $91K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.8% | 74 | 66 | $2K |
| 80305 | <1% | 264 | 238 | $514.40 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 336 | 327 | $204.46 |
| 1036F | 0% | 1,598 | 1,447 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 1,591 | 1,440 | $0.00 |
| G9907 | Documentation of medical reason(s) for not providing tobacco cessation intervention on the date of the encounter or within the previous 12 months (e.g., limited life expectancy, other medical reason) | 0% | 2,467 | 2,219 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 35 | 29 | $0.00 |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 1,198 | 1,085 | $0.00 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 60 | 50 | $0.00 |
| G9970 | Clinician who referred the patient to another clinician did not receive a report from the clinician to whom the patient was referred | 0% | 44 | 38 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 1,279 | 1,121 | $0.00 |
9 more codes
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 1,873 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 1,238 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 1,583 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 1,591 | $0.00 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 1,215 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 760 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 784 | $0.00 |
| 4004F | 0% | 60 | $0.00 | |
| 4040F | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBURKHEAD, DANIEL (OWNER)